Systematic Characterization of Clinically Actionable Antibody-Drug Targets Across Solid Tumors to Advance Precision Oncology
The rapid expansion of antibody therapeutics is shifting the clinical bottleneck from drug availability to precise patient selection. We systematically characterize 87 clinically actionable tumor-associated antigens across solid tumors by integrating transcriptomic, proteomic, spatial, and single-cell profiles from more than 32,000 specimens to define expression prevalence, intratumoral heterogeneity, immune contexture, internalization and payload-sensitivity pathways, and translational relevance. We establish ANCHOR, a coordinate reference framework for standardizing patient RNA-seq data, and develop ReSort, a two-tiered scoring system for scalable target prioritization. ReSort enables virtual basket and umbrella trial matching, demonstrates concordance with clinical assays, predicts therapeutic response in patient-derived models, and identifies repurposing opportunities in rare malignancies. We develop an AI-based decision-support agent for antibody trial matching and construct a multimodal feature space integrating tumor- and protein-intrinsic attributes to guide systematic target discovery and prioritization. This work provides a scalable, clinically actionable approach for precision antibody-based therapies and next-generation target development.
Authors
- Angela M. DeMichele (ORCID: https://orcid.org/0000-0003-1297-4251)
- Enjun Yang (ORCID: https://orcid.org/0000-0003-1511-7511)
- Ravi K. Amaravadi (ORCID: https://orcid.org/0000-0002-5768-2474)
- Yi Fan (ORCID: https://orcid.org/0000-0002-6290-0595)
- Eleanor Taranto (ORCID: https://orcid.org/0000-0002-0299-2176)
- Josh Sommer (ORCID: https://orcid.org/0000-0001-6780-1871)
- Tong Su (ORCID: https://orcid.org/0000-0002-4177-522X)
- Jeffrey Kaufman (ORCID: https://orcid.org/0000-0002-0084-5826)
- Zhongyi Hu (ORCID: https://orcid.org/0000-0002-9249-9720)
- Daniel M. Freed (ORCID: https://orcid.org/0000-0002-3564-6376)
- Janos Laszlo Tanyi (ORCID: https://orcid.org/0000-0002-5657-3698)
- Jiao Yuan (ORCID: https://orcid.org/0000-0003-2597-2319)
- Robert H. Vonderheide (ORCID: https://orcid.org/0000-0002-7252-954X)
- Xiaowen Hu (ORCID: https://orcid.org/0000-0002-3269-4356)
- Yuxin Wang (ORCID: https://orcid.org/0000-0002-0386-9911)
- Jennifer Q. Zhang (ORCID: https://orcid.org/0000-0002-0732-9939)
- Christopher R. Cabanski (ORCID: https://orcid.org/0009-0007-9938-1331)
- Junjie Nie (ORCID: https://orcid.org/0009-0005-7528-2174)
- Nicole Spardy Burr (ORCID: https://orcid.org/0009-0004-7581-8947)
- Susan M. Domchek (ORCID: https://orcid.org/0000-0002-5914-7272)
- Hongzhe Li (ORCID: https://orcid.org/0000-0003-3662-3907)
- Meixiao Long (ORCID: https://orcid.org/0000-0002-0820-5612)
- Kathleen T. Montone (ORCID: https://orcid.org/0000-0002-5794-3371)
- Lin Zhang (ORCID: https://orcid.org/0000-0003-1998-0611)
- Yanrong Sun (ORCID: https://orcid.org/0000-0001-9921-4882)
- Junjie Jiang (ORCID: https://orcid.org/0009-0000-8008-1557)
- Jie Huang (ORCID: https://orcid.org/0009-0006-1871-0598)
- Sarah H. Kim (ORCID: https://orcid.org/0000-0003-1381-6781)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Sun Yat-sen University (CN)
- Hospital of the University of Pennsylvania (US)
- Guangzhou Experimental Station (CN)
- Chordoma Foundation (US)
- Parker Institute for Cancer Immunotherapy (US)
- Guangzhou Chemistry (China) (CN)
- Adenoid Cystic Carcinoma Research Foundation (US)
- Obstetrics and Gynecology Hospital of Fudan University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangzhou Laboratory (CN)
- Nanjing First Hospital (CN)
- The Ohio State University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1158/2159-8290.cd-26-1021
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00